Log in to save to my catalogue

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2534610901

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has demonstrated 95% efficacy in preventing COVID-19
1
. Here we extend a previous phase-I/II trial report
2
by presenting data on the immune response induced by BNT162b2 pri...

Alternative Titles

Full title

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2534610901

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2534610901

Other Identifiers

ISSN

0028-0836,1476-4687

E-ISSN

1476-4687

DOI

10.1038/s41586-021-03653-6

How to access this item